The company hopes that its novel approach in Friedreich’s ataxia could still have legs, but other assets are further ahead.
A solo drug launch is a testing time for a small company, made even tougher by the pandemic.
Large numbers of blank-cheque groups are seeking deals, but the bloom might be coming off the rose.
If drugs acting on amyloid and tau can defy the sector’s history of failure, the testing landscape will change dramatically.
The failure of Roche and Ionis’s late-stage candidate tominersen casts doubt on Wave’s approach, too.
Early data could give clues about whether gene therapies from Sio, Passage Bio or Lysogene will come out on top in this rare inherited disease.
New findings for IL-6 blockade in the Recovery trial finally confirm a signal. Can pending pandemic readouts for other mechanisms do the same?
Development of new drugs for this hard-to-treat brain cancer is a slow and incremental process.
Galapagos is betting big in IPF but others, including Fibrogen and Roche, are also taking aim at the lung disease.